跳至主要内容
临床试验/NCT03782103
NCT03782103已完成3 期

Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep

Zurex Pharma, Inc.1 个研究点 分布在 1 个国家目标入组 156 人开始时间: 2019年1月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
156
试验地点
1
主要终点
Bacterial Reduction - Groin

研究概览

简要总结

The objective of the study is to demonstrate the antimicrobial efficacy of the Zurex Preoperative Prep (ZuraPrep - clear) on skin flora of the abdomen and inguinal regions of human subjects.

详细描述

The primary objective of this study is to measure the antimicrobial effectiveness of a single investigational test article, ZuraPrep™ as specified by the Healthcare Antiseptics, Topical Antimicrobial Drug Products Final Rule of December 20, 2017. The treatments will be ZuraPrep™ as the investigational test article, ChloraPrep® as an active control, and ZuraPrep™ Vehicle as a negative control. For efficacy at 30 seconds post-prep, the test article should be superior to the negative control using a margin of 1.2 log10 CFU/cm2 and non-inferior to the active control using a margin of 0.5 log10 CFU/cm2.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects of any race
  • Subjects in good general health
  • Minimum bacterial baseline requirements on abdomen and groin
  • Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder near or on the applicable test area.

排除标准

  • Topical or systemic antimicrobial exposure within 14 days prior to screening and treatment days, including antibiotics.
  • Taking antihistamines, immunosuppressants, or oral steroids within 14 days prior to screening and treatment days, excluding contraception or post-menopausal treatment.
  • Subjects with allergies to study materials including isopropyl alcohol or chlorhexidine gluconate.
  • Subjects with a history of skin sensitivity, skin allergies, or skin cancer.
  • Subjects who are pregnant, attempting pregnancy or nursing.

研究组 & 干预措施

ZuraPrep (70% IPA)

Experimental

Isopropyl alcohol (IPA) 70%

干预措施: ZuraPrep Clear Solution (Drug)

ChloraPrep

Active Comparator

Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%

干预措施: ChloraPrep (Drug)

ZuraPrep Vehicle

Placebo Comparator

Zurex Prep without IPA

干预措施: ZuraPrep Vehicle (Drug)

结局指标

主要结局

Bacterial Reduction - Groin

时间窗: 30 seconds post product application

A 3-log10 CFU/cm\^2 bacterial reduction on the inguinal region is considered a success.

Bacterial Reduction - Abdomen

时间窗: 30 seconds post product application

A 2-log10 CFU/cm\^2 bacterial reduction on the abdomen region is considered a success.

次要结局

  • Bacterial Counts Not Exceeding Baseline in the Abdomen and Groin Region(6 hours post product applcation)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验